R Squared’s Coherus Oncology CHRS Stock Holding History

R Squared’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-140	Closed	-$193	–	527
2024 Q4	$193	Buy	+140	New	+$157	﹤0.01%	1557

Other funds holding CHRS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

R Squared's CHRS Position: Q1 2025 in Review

R Squared sold out of Coherus Oncology (CHRS) in Q1 2025, closing a stake of 140 shares — an estimated $193 sold.

R Squared first reported a position in CHRS in Q4 2024 and held it in 1 quarter. The position peaked at $193 in Q4 2024. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2025.

R Squared reported no remaining Coherus Oncology position as of Q1 2025 after selling out during the quarter.
R Squared sold 140 Coherus Oncology shares in Q1 2025, an estimated $193.
R Squared first reported a position in Coherus Oncology in Q4 2024 and held it in 1 quarter.
R Squared's Coherus Oncology position peaked at $193 in Q4 2024.
117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.